Cooperative Agreement R43CA196101

This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $632,300 to Carnegie Mellon University to develop an integrated ultrahigh-throughput 3D volumetric super-resolution imaging system. This system will combine a multiscale fluorescence mesoscope with expansion microscopy to enable rapid, large-area 3D imaging at subcellular resolution. The goal is to advance the application of spatial biology in cancer research by visualizing...

This federal Cooperative Agreement award, issued by the Department of the Interior's Interior Business Center under the Advanced Research Projects Agency for Health (ARPA-H) program (CFDA 93.384), supports the development of a novel imaging technology called "VISION" that enables real-time, high-resolution intraoperative detection of microscopic residual cancer cells during surgical procedures. The $5,160,920 award to the Regents of the University of California, San Francisco aims to...

Federal Cooperative Agreement Summary Yale University received a $251,360 Cooperative Agreement from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394) effective September 1, 2025, through August 31, 2027. The award supports the development and validation of multiplexed quantitative immunofluorescence (MQIF) assays designed to measure spatially resolved tissue biomarkers in formalin-fixed paraffin-embedded tumor biopsies. These assays will...

The University of Michigan has been awarded a $568,151 Project Grant from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to develop a real-time functional imaging platform for accurate diagnosis and prognosis of prostate cancer. The project aims to leverage photoacoustic imaging and biocompatible hydrogel nanoparticle probes to quantitatively assess prostate gland microarchitecture and tumor microenvironment as imaging biomarkers for improved prostate...

This $516,355.74 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, aims to develop new technologies for immunotherapy monitoring and liquid biopsy through the Cancer Research Manpower federal grant program. Specifically, the Massachusetts General Hospital will utilize the funding to create an ultra-high sensitive platform that can map single extracellular vesicles to parent cells at the single particle level and apply it to profile tumor...

Visikol Inc. received a $4,103,265 Project Grant award from the National Cancer Institute, a division of the Department of Health and Human Services, under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The award will support the development of a 3D imaging diagnostic tool to improve characterization of metastatic melanoma in sentinel lymph node biopsies. Visikol will conduct a retrospective clinical study using archived negative sentinel lymph node biopsy tissue blocks to...

This Project Grant award of $162,080, made by the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398), supports research conducted by The Johns Hopkins University from December 27, 2025 through June 30, 2028. The funded research, led by Dr. Komatsu's laboratory, focuses on visualizing B cell infiltration and aggregation within the tumor microenvironment to advance cancer immunotherapy development. The project delivers foundational scientific insights through...

This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $457,683 to the Beckman Research Institute of the City of Hope to develop and evaluate novel "Bio-Beacons" - tumor-targeting bacterial vectors engineered to secrete chemokines and cytokines. The goal is to increase the density of tumor-reactive immune cells, such as CD8 T cells, CD4 T cells, dendritic cells, and natural killer cells, within solid tumors. This is...

This $399,499 Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports the development of Liquid Biotech's TELOMESCAN circulating tumor cell (CTC) assay for monitoring non-small cell lung cancer (NSCLC) patients undergoing radiation and immunotherapy. The key products and services to be delivered through this funding include: 1) Developing a clinical prototype of the TELOMESCAN assay with automated analysis to...

This $500,000 Project Grant from the National Science Foundation's Division of Chemistry, under the Mathematical and Physical Sciences program (CFDA 47.049), supports research at Southern Methodist University to advance quantitative chemiluminescence imaging techniques. Professor Alexander Lippert will develop near-infrared and short-wave infrared ratiometric chemiluminescent probes, kinetics-based probes, and microscopy methods to enable precise quantification of analytes like oxygen, pH,...